arrow
C

Carlo Alberto Giorgi

Veneto Institute of Oncology IOV—IRCCS
H指数:14
被引数:867

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term outcome of isolated locoregional (ILRR) breast cancer (BC) recurrence: a large retrospective Mono-institutional study

孤立性局部区域(ILRR)乳腺癌(BC)复发的长期结局:一项大型回顾性单机构研究

2026-05-010
OA
PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: a multicentric real-world study.

PIK3CA突变和内分泌抵抗性HR+/HER2-转移性乳腺癌的一线治疗效果:一项多中心真实世界研究。

2025-12-190
PREAI
Temporal evolution of breast cancer brain metastases treatments and outcomes
2025-02-200
OA
PD-L1 expression in ER-low versus triple-negative (TN) advanced breast cancer (aBC), and according to phenotypic evolution from primary to recurrent disease

PD-L1在ER低表达型与三阴性(TN)晚期乳腺癌(aBC)中的表达,以及根据从原发到复发病灶表型演化的表达情况

2024-09-010
PRE
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors

外周血淋巴细胞预测接受CDK4/6抑制剂治疗的激素受体阳性HER2-negative晚期乳腺癌患者的临床结局

2023-12-201
OAAI
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023-04-1715
OAAI
The impact of the COVID19 pandemic on treatment practices for patients diagnosed with early breast cancer: a cross-sectional study from a large comprehensive cancer centre in Italy
2023-03-010
PRE
HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy
2023-03-013
PRE
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (vol 128, pg 266, 2022)
2022-12-020
OA
Optimizing CDK4/6 inhibitors in advanced HR+/HER2-breast cancer: A personalized approach

优化晚期HR /HER2-breast癌症中的CDK4/6抑制剂: 个性化方法

2022-12-013
OAAI
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
2022-11-177
OA
HER2DX genomic test in HER2-positive/hormone receptorpositive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial

新辅助曲妥珠单抗和帕妥珠单抗治疗HER2-positive/激素受体阳性乳腺癌的HER2DX基因组检测: 来自PerELISA试验的相关分析

2022-11-0123
OAAI
HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial
2022-09-010
OA
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial

依维莫司联合芳香化酶抑制剂作为一线化疗后的维持治疗: III期随机main-a (维持Afinitor) 试验的最终结果

2021-09-0110
OAAI
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)
2021-03-305
OA